title: Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
abstract: Uterine myomas are the most common gynecologic tumor in women of reproductive age. Treatment options of uterine myomas consist of surgical, medical and interventional therapy such as uterine artery embolization or myolysis. Given that it is the most common type of tumor in women of reproductive age, the treatment of uterine myomas must prioritize uterine conservation. There are several drugs for medical treatment of uterine myoma such as gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM) and antiprogesterone. The objective of this study was to compare the effect of GnRH agonist, SERM, and antiprogesterone in the treatment of uterine myomas in vitro. The effect of drugs was evaluated through the cell viability assay in cultured leiomyoma cells, western blot analysis of proliferating cell nuclear antigen (PCNA), and BCL-2 protein expression. As a result, mifepristone single-treated group represents the most significant reduction in myoma cell viability and proliferation. When pretreated with leuprolide acetate, raloxifene shows more significant reduction in myoma cell viability and proliferation than mifepristone. This study suggests one of the possible mechanisms how medications act on uterine myoma, especially at the molecular level.
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Youn-Jee
authors: YJ
authors: Chung
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Boah
authors: B
authors: Chae
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Se-Hyun
authors: SH
authors: Kwak
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Jae-Yen
authors: JY
authors: Song
authors: 2. Department of Hospital Pathology, The Catholic University of Korea, Republic of Korea.
authors: Ah-Won
authors: AW
authors: Lee
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Hyun-Hee
authors: HH
authors: Jo
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Young-Ok
authors: YO
authors: Lew
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Jang-Heub
authors: JH
authors: Kim
authors: 1. Department of Obstetrics and Gynecology, The Catholic University of Korea, Republic of Korea.
authors: Mee-Ran
authors: MR
authors: Kim
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D066298:In Vitro Techniques; D007889:Leiomyoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009214:Myoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011374:Progesterone / Q000037:antagonists & inhibitors*; D018809:Proliferating Cell Nuclear Antigen / Q000096:biosynthesis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D012098:Reproduction / Q000187:drug effects; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D018809:Proliferating Cell Nuclear Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D020845:Selective Estrogen Receptor Modulators; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone
keywords: Drug therapy; Gonadotropin-releasing hormone agonist; Leiomyoma; Mifepristone; Raloxifene